Thursday, January 20, 2022

ImmPACT Bio Lands $111M For Cancer Therapy

Camarillo-based ImmPACT Bio, a company developing cancer therapies, said this week that it has raised $111M in a Series B financing round. The funding was led by venBio Partners, along with Foresite Capital and Decheng Capital, plus Surveyor Capital (a Citadel company), OrbiMed, Novartis Venture Fund, RM Global Partners (RMGP), and Bukwang Pharmaceutical. According to the company, the new funding will go to advance its next-generation CAR T-cell therapies. The company said it has named Sheila Gujrathi, M.D. as new board chair and appointed new president and CEO Sumant Ramachandra, M.D., Ph.D., M.B.A., as part of the funding.